Microsoft word - r1556492

Material Safety Data Sheet
1. PRODUCT AND COMPANY IDENTIFICATION
This Material Safety Data Sheet was prepared for the jurisdiction USA. Sterile Triamcinolone Acetonide Suspension USP; Kenalog-10 Injection; Kenalog-40 Injection This material is a finished drug product for patient use. This material is used to provide relief of inflammatory and pruritic skin conditions. Company/Undertaking Identification Bristol-Myers Squibb Company
P.O. Box 191
New Brunswick, New Jersey 08903
United States of America
1-732-227-7380
CHEMTREC 1-800-424-9300. For all international transportation emergencies call CHEMTREC at 1-703-527-3887. Collect calls accepted. 2. COMPOSITION/INFORMATION ON INGREDIENTS
3. HAZARDS IDENTIFICATION
Teratogen May be harmful to fetus. Reproductive toxicant Target Organs: adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, (embryo/fetus). Kenalog Injection (10 or 40 mg/ml) Bristol-Myers Squibb Company
Page 2 of 10
3. HAZARDS IDENTIFICATION
Avoid ingestion, inhalation, skin and eye contact. Wash hands after handling to minimize exposure. Wear suitable protective clothing and gloves. Pregnant or nursing women should avoid exposure. Prevent release to the environment. Rapidly absorbed through skin., Repeated exposure may cause skin dryness or cracking., May be harmful if absorbed through skin. May cause damage to organs through prolonged or repeated exposure if swallowed. May cause damage to organs through prolonged or repeated exposure if inhaled. adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, (embryo/fetus) Chronic: muscle weakness, muscle pain, bone fractures, infection, oedema, headache, difficulty sleeping, vertigo, restlessness, euphoria, mental disturbance, depression, anxiety, mood changes, seizure disorders, nosebleeds, cough, fever, nausea, vomiting, anorexia, gastrointestinal disturbance, sore throat, dry mouth, taste disturbance, speech difficulty, congestion, redness and swelling of eyes, vision changes, facial swelling, skin thinning, acne, redness and swelling of skin, hives, bruising, superficial burning sensation, tingling. diabetes, Liver disorders, infection, immunodeficiency, hypertension, myasthenia gravis, osteoporosis, peptic ulcer, psychotic disorders, colitis, kidney disorders 4. FIRST AID MEASURES
Rinse immediately with plenty of water for at least 15 minutes. Keep eye wide open while rinsing. Obtain medical attention. Take off contaminated clothing and shoes immediately. Wash off immediately with plenty of water for at least 15 minutes. Obtain medical attention. Wash contaminated clothing before re-use. Move to fresh air. Oxygen or artificial respiration if needed. Obtain medical attention. Do NOT induce vomiting. Consult a physician if necessary. Never give anything by mouth to an unconscious person. Kenalog Injection (10 or 40 mg/ml) Bristol-Myers Squibb Company
Page 3 of 10
4. FIRST AID MEASURES
This material is a finished drug product for patient use. This material is used to provide relief of inflammatory and pruritic skin conditions. This product may cause: muscle weakness, muscle pain, bone fractures, infection, oedema, headache, difficulty sleeping, vertigo, restlessness, euphoria, mental disturbance, depression, anxiety, mood changes, seizure disorders, nosebleeds, cough, fever, nausea, vomiting, anorexia, gastrointestinal disturbance, sore throat, dry mouth, taste disturbance, speech difficulty, congestion, redness and swelling of eyes, vision changes, facial swelling, skin thinning, acne, redness and swelling of skin, hives, bruising, superficial burning sensation, tingling, increase in blood pressure, Cushing's syndrome, electrolyte disturbance, hyperglycemia, adrenocortical insufficiency, withdrawal symptoms, osteoporosis, bone effects, menstrual irregularities, sperm abnormalities, cataracts, glaucoma, nose changes, otitis, peptic ulcer, psychotic disorders, pancreatitis, changes in white blood cell parameters. Organs effected may include: adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, (embryo/fetus). Medical conditions aggravated include: diabetes, Liver disorders, infection, immunodeficiency, hypertension, myasthenia gravis, osteoporosis, peptic ulcer, psychotic disorders, colitis, kidney disorders. This product has been reported to interact with the following medications: diuretic, cyclosporine, immunosuppressants, NSAID (non-steroidal antiinflammatory drugs), drug metabolized by cytochrome P-450, drugs that cause hyperglycemia, oral hypoglycemic drugs, neuromuscular blocking agents, fluoroquinoline antibiotics, certain vaccines, drugs that inhibit cytochrome P-450. Refer to Section 11. Pregnant or nursing women should avoid exposure. A pre-placement physical examination and history for employees with potential exposure to this compound is recommended. Baseline testing would include: Pre-placement:, blood glucose test, a complete blood count with differential. Based on opportunity for exposure and duration of exposure a periodic follow-up examination may be considered. Employees, who are pregnant, are breast-feeding, or who are concerned with other reproductive issues should be encouraged to consult with the occupational health physician monitoring worker's health. 5. FIRE-FIGHTING MEASURES
Suitable extinguishing media: Dry chemical, Water spray, Foam Unsuitable extinguishing media: Do NOT use water jet. Specific hazards: Teratogen skin absorption hazard Protective equipment: Use personal protective equipment. In the event of fire, wear Hazardous Combustion Products: carbon oxides, hydrogen halides Decontaminate protective clothing and equipment before reuse. Heating can release hazardous gases. HCl gas can form flammable or explosive mixtures with alcohols or metals. 6. ACCIDENTAL RELEASE MEASURES
Refer to protective measures listed in sections 7 and 8. Use personal protective equipment. Examples include tightly fitting safety goggles, disposable lab coat of low permeability with cuffs, double gloves and shoe covers. Wear respiratory protection. Depending on the nature of the spill (quantity and extent of spill) additional protective clothing and equipment such as a self-contained breathing apparatus may be needed. Kenalog Injection (10 or 40 mg/ml) Bristol-Myers Squibb Company
Page 4 of 10
6. ACCIDENTAL RELEASE MEASURES
Prevent release to drains and waterways. Prevent release to the environment. Containment Methods Contain spillage, and then collect with non-combustible absorbent material, (e.g. sand, earth, diatomaceous earth, vermiculite) and place in container for disposal according to local / national regulations (see section 13).
Source: http://westernunew.com/bin/safety/msds/pcc/Kenalog%20Injection.pdf